Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease

Figure 1 Frequency of liver fibrosis risk in patients with metabolic-dysfunction-associated fatty liver disease according to fibrosis-4, nonalcoholic fatty liver disease score and aspartate aminotransferase-to-platelet ratio index, n (%). APRI: Aspartate aminotransferase-to-platelet ratio index; NAFLD: Nonalcoholic fatty liver disease; FIB-4: Fibrosis-4.